A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors. (December 2016)

Record Type:: Journal Article
Title:: A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors. (December 2016)
Main Title:: A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors
Authors:: Razak, A.
Gore, L.
Britten, C.D.
Miller, W.H.
Uy, G.L.
Nichols, G.
Middleton, S.
Blotner, S.
Zhi, J.
Jukofsky, L.
Pierceall, W.
Higgins, B.
Chen, L.C.
Abstract:
Is Part Of:: European journal of cancer. Volume 69(2016)supplement 1
Journal:: European journal of cancer
Issue:: Volume 69(2016)supplement 1
Issue Display:: Volume 69, Issue 2016 (2016)
Year:: 2016
Volume:: 69
Issue:: 2016
Issue Sort Value:: 2016-0069-2016-0000
Page Start:: S21
Page End:: S22
Publication Date:: 2016-12
Subjects:: Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994
Journal URLs:: http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0959-8049(16)32645-4 ↗
Languages:: English
ISSNs:: 0959-8049
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 2627.xml